U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Sample 5

Identifiers
BioSample: SAMEA4716191; SRA: ERS2536340
Organism
Homo sapiens (human)
cellular organisms; Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata; Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Boreoeutheria; Euarchontoglires; Primates; Haplorrhini; Simiiformes; Catarrhini; Hominoidea; Hominidae; Homininae; Homo
Attributes
cell lineMCF-7
cell typemammary epithelial cell
diseaseinvasive ductal carcinoma
tissuemammary gland
sample nameE-MTAB-6871:Sample 5
ENA-CHECKLISTERC000011
ENA-FIRST-PUBLIC2019-02-08T17:04:04Z
ENA-LAST-UPDATE2018-06-07T16:31:53Z
External IdSAMEA4716191
INSDC center nameLaboratory of Molecular Medicine and Genomics
INSDC first public2019-02-08T17:04:04Z
INSDC last update2018-06-07T16:31:53Z
INSDC statuspublic
Submitter IdE-MTAB-6871:Sample 5
broker nameArrayExpress
common namehuman
metastatic sitepleural effusion
scientific_nameHomo sapiens
Description

Protocols: ER-alpha positive BC cells: MCF-7 (ATCC HTB-22) were propagated in Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich) supplemented with 10% FBS (HyClone) and antibiotics: 100 U/ml penicillin, 100 mg/ml streptomycin, 250 ng/ml amphotericin-B. MCF-10A (ATCC CRL-10317) was cultured in Mammary Epithelial Cell Growth Medium (MEGM BulletKit, Lonza, Catalog No. CC-3150) with added 100 ng/ml cholera toxin. None ER-alpha positive BC cells: MCF-7 (ATCC HTB-22) were propagated in Dulbecco’s modified Eagle medium (DMEM; Sigma-Aldrich) supplemented with 10% FBS (HyClone) and antibiotics: 100 U/ml penicillin, 100 mg/ml streptomycin, 250 ng/ml amphotericin-B. Cells were treated with ICI 182,780 10-7 M for 3 days and with EPZ004777 6.4 µM or DMSO for 3 and 6 days. Conversion from BCL to fastq was perfromed using BCL2Fastq 104cells/well were incubated with compounds for 3 or 6 days with media containing compounds or vehicle and in particular MCF-7 cells treated with EPZ004777 6.4µM or DMSO for for 3 and 6 days or with 4-hydroxytamoxifen 10-7 M (4-OHT) or fulvestrant 10-7 M (ICI 182,780) or DMSO for 3 days. LCC2 cells were treated with 4-hydroxytamoxifen 10-7 M (4-OHT) or DMSO for 3 days and medium replaced every 2 days. Medium was replaced every 2 days. Total RNA was extracted using standard RNA extraction method with TRIzol (Invitrogen). 0.3-0.4 mL of TRIzol™ Reagent per 1 × 105-107cells was added directly to the culture dish to lyse the cells pipetting several times to homogenize. Then was added 0.1 ml of 1-Bromo-3-chloropropane (Sigma- Aldrich) and after incubation of 2-3 minutes, the samples was centrifugated for 15 minutes at 12,000 × g at 4°C. Then, the aqueous phase, containing the RNA, was collected into a new tube and precipitate with isopropanol and resuspended in RNAse/DNase free water. Nascent RNA was extracted from each sample as described by Khodor et al. In brief, following TRIzol (Life Techonolgies) addition, samples were incubated at 65°C to dissolve DNA-Histone-Pol II-RNA pellets and RNA was extracted following the manufacturer’s protocol. For sequencing, indexed libraries were prepared using 1 µg of Nascent RNA as starting material, with TruSeq Stranded Total RNA Sample Prep Kit (Illumina Inc.).

BioProject
PRJEB27185 NascentSeq of human breast cancer cell MCF7 treated with EPZ, ICI and DMSO at 3 or 6 days
Retrieve all samples from this project

Submission
EBI; 2019-02-14
Accession:
SAMEA4716191
ID:
10933781

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center